CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：CARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic Malignancies.
CARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic Malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法已彻底改变血液系统恶性肿瘤的治疗。目前，CAR-T 已获批用于多种淋巴瘤、白血病和骨髓瘤。随机临床试验显示，在弥漫性大 B 细胞淋巴瘤（DLBCL）和多发性骨髓瘤（MM）中，CAR-T 细胞疗法较标准治疗可改善生存，显著改变了当前治疗模式。目前的研究重点是在一线治疗中改善结局，且确证性随机试验仍在进行。
Chimeric antigen receptor T-cell (CAR-T) has revolutionized the treatment of hematologic malignancies. There are several approvals in lymphomas, leukemias and myeloma. Randomized clinical trials have shown that CAR-T cell therapy improves survival over standard of care in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM), changing dramatically the current treatment paradigm. Current efforts are directed in improving outcomes in the frontline setting and confirmatory randomized trials are ongoing.
MEMBER ACCOUNT
登录成功会直接打开下一页。
